SCHEMBL689422

SCHEMBL689422

Brc1cccc(N2CCNCC2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 7/20 0.62
HTR1A P08908 6/20 0.62
ADRB1 P08588 5/20 0.62
HTR3E A5X5Y0 4/20 0.62
HTR3B O95264 4/20 0.62
HTR3A P46098 4/20 0.62
HTR3D Q70Z44 4/20 0.62
HTR3C Q8WXA8 4/20 0.62
SIGMAR1 Q99720 4/20 0.62
HTR2C P28335 3/20 0.62
THRB P10828 2/20 0.62
HTR6 P50406 2/20 0.62
TP53 P04637 1/20 0.62
CYP1A2 P05177 1/20 0.62
CYP3A4 P08684 1/20 0.62
CYP2D6 P10635 1/20 0.62
CYP2C9 P11712 1/20 0.62
HTR2A P28223 1/20 0.62
SLC6A4 P31645 1/20 0.62
CYP2C19 P33261 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4661519 0.98 HTR7 (0.61) HTR7HTR1AADRB1HTR3EHTR3B
SCHEMBL28079384 0.89 HTR7 (0.50) HTR7HTR1AADRB1HTR3EHTR3B
Tert-Butyl Formate SCHEMBL27824904 0.83 ADRB1 (0.50) HTR7HTR1AADRB1HTR3EHTR3B
SCHEMBL1699410 0.82 DHFR (0.50) ALDH1A1
SCHEMBL1353556 0.82 MEN1 (0.52) HTTALDH1A1MAPT
Tert-Butyl Formate SCHEMBL28119361 0.82 ADRB1 (0.49) HTR7HTR1AADRB1HTR3EHTR3B
SCHEMBL17276711 0.80 ADRB1 (0.67) HTR7HTR1AADRB1HTR3EHTR3B
SCHEMBL2174158 0.80 ALDH1A1 (0.50) HTTALDH1A1MAPT
SCHEMBL265128 0.80 ALDH1A1 (0.50) HTTALDH1A1MAPT
SCHEMBL30087959 0.79 CHRNB2 (0.47) HTR7HTR1AADRB1HTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108017659-A Benzimidazole and thiazole carboxamides class compound and its application 沈阳药科大学 2018-05-11 CN claimed
US-20260109708-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE CELGENE CORP (US) 2026-04-23 US disclosed
US-20250388584-A1 TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME SHANGHAI RAISING PHARMACEUTICAL CO LTD (CN) 2025-12-25 US disclosed
EP-4661875-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE Celgene Corporation (US) 2025-12-17 EP disclosed
EP-4556007-A1 TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME Shanghai Raising Pharmaceutical Co., Ltd. (CN) 2025-05-21 EP disclosed
CN-119497615-A TPK agonists and methods of using the same for treating neurodegenerative diseases 上海日馨医药科技股份有限公司 2025-02-21 CN disclosed
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2025-01-23 US disclosed
WO-2024260023-A1 CYCLIC Α-HYDROXYIMIDE COMPOUND AND USE THEREOF 北京英飞智药科技有限公司 2024-12-26 WO disclosed
CN-116444461-B Dibenzylbutane lignan LCA derivative and application thereof 中国人民解放军海军军医大学 2024-12-24 CN disclosed
CN-119176777-A Cyclic alpha-hydroxyimide compound and application thereof 北京英飞智药科技有限公司 2024-12-24 CN disclosed
US-5627196-A ANTIDEPRESSANTS AND ANTISEROTONIN AGENTS ELI LILLY AND COMPANY (US) 1997-05-06 US disclosed
US-5614523-A INDOLYLOXY COMPOUNDS ELI LILLY AND COMPANY (US) 1997-03-25 US disclosed
EP-0749425-A1 NEW PIPERAZINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME SAMJIN PHARM. CO., LTD. (KR) 1996-12-27 EP disclosed
US-5576321-A ALKOXY-SUBSTITUTED INDOLES ELI LILLY AND COMPANY (US) 1996-11-19 US disclosed
WO-1996022290-A1 COMPOUNDS HAVING EFFECTS ON SEROTONIN-RELATED SYSTEMS ELI LILLY AND COMPANY (US) 1996-07-25 WO disclosed
EP-0722941-A2 Compounds having effects on serotonin-related systems ELI LILLY AND COMPANY (US) 1996-07-24 EP disclosed
WO-1996021648-A1 NEW PIPERAZINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME SAMJIN PHARMACEUTICAL CO., LTD. (KR) 1996-07-18 WO disclosed
EP-0015615-B1 PHENYL PIPERAZINE DERIVATIVES, THEIR PREPARATION AND ANTIAGRESSIVE MEDICINES CONTAINING THEM DUPHAR INTERNATIONAL RESEARCH B.V (NL) 1983-01-12 EP disclosed
EP-0015615-A1 Phenyl piperazine derivatives, their preparation and antiagressive medicines containing them DUPHAR INTERNATIONAL RESEARCH B.V (NL) 1980-09-17 EP disclosed
US-4123529-A TREATMENT OF ASTHMA LILLY INDUSTRIES LIMITED (GB) 1978-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA HTR7 4826/4885HTR1A 4709/4885ADRB1 4481/4885
US-20260109708-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE PSME2, MKRN3, RPS6KA2 HTR7 3543/4885HTR1A 3795/4885ADRB1 1800/4885
US-20250388584-A1 TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME PDXK, SLC19A2, NADK HTR7 418/4885HTR1A 469/4885ADRB1 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.